Company news

Evogene Ltd. news in 2026

Evogene Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

October 28, 2026

Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain

October 26, 2026

Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL

October 20, 2026

Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors

October 6, 2026

Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance

September 30, 2026

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

August 31, 2026

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

August 25, 2026

Evogene Reports Second Quarter and First Half 2026 Financial Results

August 18, 2026

Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

August 14, 2026

Evogene Schedules Second Quarter 2026 Financial Results Release

July 30, 2026

Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

July 22, 2026

AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities

July 15, 2026

Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery

July 8, 2026

Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization

June 24, 2026

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

June 8, 2026

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

June 2, 2026

Evogene Reports First Quarter 2026 Financial Results

May 20, 2026

Evogene to Present at the 24th Schrödinger European User Group Meeting

May 12, 2026

Evogene Schedules First Quarter 2026 Financial Results Release

May 7, 2026

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

April 2, 2026

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

March 31, 2026

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

March 9, 2026

Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

March 4, 2026

Evogene Releases CEO Letter to Shareholders

February 24, 2026

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

February 18, 2026

Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics

February 17, 2026

Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

February 11, 2026

Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds

February 10, 2026

Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™

February 10, 2026

Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board

February 9, 2026

Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

February 4, 2026

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

January 7, 2026

Calls in 2026

Decks in 2026